[ 电Ta 子bl 设e_ 备T 行itl 业e] 专 题研究 行 业 研 先进封装材料专题（一）：ABF载板材 究 挖掘价值 投资成长 / 料设备领航，关注玻璃基新方向 电 [Table_Rank] 子 设 强于大市 （维持） 备 2024 年 02 月 27 日 / [东Ta方bl财e_富Au证th券or研] 究所 证 证券分析师：邹杰 券 [Table_Summary] 研 【投资要点】 证书编号：S1160523010001 究 联系人：刘琦 报  先进封装产业趋势明确，重点关注工艺、材料和设备的破局之路。高 告 电话：021-23586475 算力需求驱动封装方式的演进，2.5D/3D、Chiplet等先进封装技术市 场规模逐渐扩大，多芯片、异质集成、芯片之间高速互联成为发展重 [相 T对 a指 bl数 e表 _现 Pi cQuote] 点，Intel、台积电等厂商纷纷布局。由于结构堆叠、芯片算力提升 等因素影响，先进封装技术目前还面临一些问题，例如晶圆翘曲、焊 14.30% 5.51% 点可靠性问题、TSV可靠性问题、RDL可靠性问题以及封装散热问题， -3.27% 寻找更合适的材料、采用新的工 ...

]yrtsudnI_elbaT[ 收入稳健增长，机器人和AI探索多点开 花 [Table_ 【事项Summary 】 ] 索辰科技 沪深300 [Table_Title] 索辰科技（688507）动态点评 公司也已成立大模型部门，通过机器学习和传统仿真的算法融合，以 及通过生成式大模型表现实际工况环境，以改进传统仿真将工程抽象 化建模的能力。 公司持续推动研发创新，研发投入持续增加。加强研发项目投入与人 才队伍建设，增强公司内外部竞争力。公司已经成立了机器人事业部， 将提供专为机器人设计的仿真解决方案。无论是基于模型(Model Based)还是人工智能（AI Learning Based）的技术路线，机器人运 动控制算法的开发都需要仿真的支持。一方面软件若想克服对硬件的 依赖，实现同步开发，需要借助仿真进行测试验证；另一方面，用于 机器学习训练的丰富而多样的场景也需要通过虚拟仿真来提供。公司 将提供一个虚实融合的机器人仿真解决方案，通过环境交互机制、虚 拟-现实误差迭代技术实现更精准的仿真。 索辰科技发布业绩预告，2023 年公司实现营业总收入 3.22 亿元，同 比上升 20.10%；实现营业利润 5,5 ...

] y r t s u d n I _ e l b a T [ [ 欧Ta 普bl 康e_ 视T （itl 3e 0] 0 595）动态点评 公 司 研 究 营销再优化，产品+服务终端双线持续 挖掘价值 投资成长 / 医 [Table_Rank] 药 增持 （维持） 生 物 2024 年 02 月 27 日 / 证 券 [东Ta方bl财e_富Au证th券or研] 究所 研 究 [【Tab事le_项Sum】ma ry] 证券分析师：何玮 报 证书编号：S1160517110001 告  公司发布2023年度业绩预告。23年公司归母净利润预计6.24-7.17亿 联系人：何玮 元，同比增长0%-15%，扣非净利润5.60-6.15亿元，同比增长0%-10%。 电话：021-23586471 23 年公司硬性角膜接触镜类产品、框架眼镜及其他产品、医疗服务等 [相T对ab指le数_P表ic现Qu ote] 三类业务实现增长，但收入占比最大的硬性角膜接触镜类产品销售收入 同比增幅不高，护理产品的收入则出现下降，整体情况符合预期。 6.14% -5.28% -16.71% 【评论】 -28.14%2/27 4/27 6 ...

]yrtsudnI_elbaT[ 世华科技 沪深300 [Table_Title] 世华科技（688093）动态点评 2024 年 02 月 27 日 【评论】 2024 年 2 月 24 日，世华科技公告 2023 年业绩预告，报告期内，公司 实现营业总收入 51,149.97 万元，同比增长 10.64%；实现归母净利润 19,349.05 万元，同比增长 4.38%；实现扣非归母净利润 16,648.51 万 元，同比增长 0.60%。截至报告期末，公司总资产为 208,588.66 万元， 较期初增长 41.69%；归属于母公司的所有者权益为 189,177.83 万元， 较期初增长 33.70%，总资产和所有者权益增长主要系公司完成定增项 目所致。 消费电子景气拐点已至，下游需求复苏拉动。公司主营的功能性材料 广泛用于消费电子、可穿戴设备等领域，公司业务与下游消费电子等行 业的景气度高度相关。根据 Canalys 市场研究机构数据，2023Q4 以来， 消费电子领域出现企稳回升的趋势，全球全年智能手机出货量跌幅收 窄，全球个人电脑出货量结束了连续七个季度的同比下滑后同比增长 3%，全球智能手表和 T ...

【风险提示】 全球经济下行，海外需求下降； AI麦可助手获客不及预期； 研发不及预期，AI麦可升级遇瓶颈。 | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

[ 交Ta 运bl 设e_ 备T 行itl 业e] 动 态点评 行 业 研 究 降低物流成本，提物流效率促行业发展 挖掘价值 投资成长 / 交 [Table_Rank] 运 设 强于大市 （维持） 备 2024 年 02 月 26 日 / [东Ta方bl财e_富Au证th券or研] 究所 证 [Table_Summary] 证券分析师：高博文 券 【事项】 研 证书编号：S1160521080001 究 证券分析师：陈子怡 报  2月23日下午，中央财经委员会第四次会议召开，习近平主席在会上 告 证书编号：S1160522070002 发表重要讲话强调，物流是实体经济的“筋络”联接生产和消费、内 贸和外贸，必须有效降低全社会物流成本，增强产业核心竞争力，提 联系人：刘雪莹 高经济运行效率。 电话：021-23586475  会议强调，降低全社会物流成本是提高经济运行效率的重要举措。物 [相 T对 a指 bl数 e表 _现 Pi cQuote] 流降成本的基本前提是保持制造业比重基本稳定，主要途径是调结 构、促改革，有效降低运输成本、仓储成本、管理成本。优化运输结 3.41% 构，强化“公转铁”、“公转水” ...

]yrtsudnI_elbaT[ 爱博医疗 沪深300 2024 年 02 月 26 日 公司发布 2023 年度业绩快报。营收预计 9.51 亿元，较上年同期的 5.79 亿元同比增长 64.18%。归母净利润预计 3.04 亿元，同比增长 30.83%， 扣非净利润预计 2.87 亿元，同比增长 38.12%。公司总资产达到 30.65 亿元，同比增长 36.58%。 23 年公司业绩预计达到较高增长。其中营收增长 64.18%，主要源于 "普诺明"等系列人工晶体收入同比增长 40%+，"普诺瞳"角膜塑形 镜收入同比增长 25%+，同时隐形眼镜及护理产品等视力保健产品快速 增长，收入占比超 15%。公司净利增速低于收入增速，在于公司隐形 眼镜业务尚处快速扩张初期，受规模效应、产线调试及品牌营销等影 响，前期盈利能力较弱。公司自年初市场恢复以来加大了整体营销投 入，加之蓬莱生产基地产能尚需逐步释放，净利增速短期受限，有待 提升。同时，公司投资收购福建优你康 51%的股权，故新增资产较高。 此外公司积极拓展了隐形眼镜业务，场地及生产线投资额也较高。 新上市及在研产品进展顺利，持续激发长期发展活力。公司新推出的 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [7]. Core Views - The company is expected to achieve a revenue of 4.394 billion yuan in 2023, representing a year-on-year growth of approximately 19.50%. The net profit attributable to shareholders is projected to grow by 1.01% to 9.15% compared to the previous year [2]. - Despite a slowdown in global economic growth affecting smartphone demand in the first half of 2023, the second half saw a recovery driven by holiday consumption and improved inventory structures among clients [2]. - The company has focused on building its own filter production lines, accelerating product iteration to meet diverse customer needs, and expanding market coverage for RF filter module products [2][3]. Summary by Sections Revenue and Profit Growth - The company reported a revenue of 4.394 billion yuan for 2023, with a growth rate of 19.48% expected for 2024 and 17.99% for 2025 [8]. - The net profit attributable to shareholders is forecasted to be 1.150 billion yuan in 2023, with growth rates of 7.57% and 19.19% for the following years [8]. Market Dynamics - The RF chip market is recovering, with inventory pressures easing in the second half of 2023 due to increased demand from domestic smartphone sales [3]. - The company has successfully established a 6-inch filter intelligent production line, enabling mass production capabilities and addressing technical challenges in filter production [3]. Product Development - The company has made significant progress in developing high-end RF filter modules, which are now entering a phase of increased delivery and market penetration [3]. - The successful development of the L-FEMiD product enhances the company's product coverage in the high-end module segment [3]. Financial Projections - The adjusted revenue forecasts for 2023, 2024, and 2025 are 4.394 billion yuan, 5.304 billion yuan, and 6.258 billion yuan, respectively [7]. - The expected earnings per share (EPS) for the same years are 2.15 yuan, 2.57 yuan, and 3.01 yuan, with corresponding price-to-earnings (P/E) ratios of 45, 38, and 33 times [7][8].

Investment Rating - The report maintains a rating of "Accumulate" for the company [22]. Core Views - The company is expected to achieve significant profit growth in 2023, with a projected net profit of 165-185 million yuan, representing a year-on-year increase of 114.61%-140.62% [1]. - The company has secured a major contract for a 6th generation flexible AMOLED module production line, with a contract value of 125 million yuan, which lays a solid foundation for its performance in 2024 [2]. - The company benefits from the ongoing domestic shift in the OLED industry, with substantial capital expenditures from panel manufacturers driving equipment procurement [21]. Financial Summary - The company’s revenue is projected to grow from 1,301.33 million yuan in 2023 to 1,942.21 million yuan in 2025, with growth rates of 33.48% and 19.64% respectively [6]. - The attributable net profit is expected to increase from 175.16 million yuan in 2023 to 259.67 million yuan in 2025, with growth rates of 127.82% and 21.04% respectively [6]. - The earnings per share (EPS) is forecasted to rise from 0.99 yuan in 2023 to 1.46 yuan in 2025 [6]. Market Position and Strategy - The company is positioned as a leader in the assembly of OLED modules and is expected to continue benefiting from the trend of domestic substitution in the OLED equipment market [15]. - The company has been increasing its R&D investment and optimizing its product structure, which has contributed to its revenue growth and improved gross margins [14][25]. - The report highlights the company's internationalization strategy and effective management as key factors in its performance [14][25].

Investment Rating - The report maintains an "Accumulate" rating for the company [11] Core Insights - The company has shown significant growth in net profit, with a year-on-year increase of 121.64% to 138.27%, expected to reach between 400 million to 430 million yuan in 2023 [9][7] - The company is focusing on four rapidly developing treatment areas: ophthalmology, medical aesthetics, orthopedics, and surgery, aiming for sustainable long-term growth through product line expansion and industry chain integration [13] - The company has successfully participated in national procurement for artificial crystals, with moderate price reductions, which may exert short-term pressure on sales but is expected to enhance market share in the long run [6][13] Financial Performance - The company’s revenue for 2023 is projected to be 2.77 billion yuan, with a growth rate of 29.96% [21] - The expected EBITDA for 2023 is 657.72 million yuan, reflecting a significant recovery from the previous year [21] - The earnings per share (EPS) for 2023 is estimated at 2.38 yuan, with a corresponding price-to-earnings (P/E) ratio of 43 [21] Product Development - The company’s third-generation hyaluronic acid product "Hai Mei" has seen a remarkable revenue increase of 377.37% in the first half of 2023, contributing to an overall growth of 114.35% in hyaluronic acid revenue [17] - The fourth-generation organic cross-linked hyaluronic acid is expected to receive approval soon, enhancing the company's competitive edge in the medical aesthetics market [17]